Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,367 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dextrose Control Clear all
Completed Phase 4 Interventional Results available

Inpatient Diabetes on Corticosteroids

NCT01970241
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
NPH, Correction Factor
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years to 79 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 24, 2026, 5:39 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Almond Effects on Glucose Intolerance Study

NCT02260895
View directory record Official record
Conditions
Prediabetes
Interventions
Almond pre-test snack
Dietary Supplement
Lead sponsor
Memorial Hermann Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 24, 2026, 5:39 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358
View directory record Official record
Conditions
Breast Neoplasms
Interventions
pembrolizumab, paclitaxel, nab-paclitaxel, liposomal doxorubicin, capecitabine, normal saline, dextrose
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Monterey, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 24, 2026, 5:39 AM EDT
Completed Not applicable Interventional

Intensive Glycemic Management and Outcomes Following Liver Transplantation

NCT01432093
View directory record Official record
Conditions
Hospital Hyperglycemia, Post-transplant Hyperglycemia
Interventions
Intensive glycemic management, Conventional management
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Oct 24, 2026, 5:39 AM EDT
Completed Phase 2 Interventional Results available

A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263

NCT01128621
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK1292263, GSK1292263 matching placebo, Sitagliptin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Chula Vista, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 24, 2026, 5:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intrapartum Glucose Management Among Women With Gestational Diabetes Mellitus

NCT02596932
View directory record Official record
Conditions
Gestational Diabetes Mellitus
Interventions
Standard Protocol for intrapartum glucose management, Experimental Protocol for intrapartum glucose management
Other
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 24, 2026, 5:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Health Literacy Intervention for African Americans With Diabetes

NCT03925948
View directory record Official record
Conditions
Uncontrolled Diabetes
Interventions
PLAN 4 Success-Diabetes
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 24, 2026, 5:39 AM EDT
Completed Phase 1 Interventional

Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group

NCT01511185
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Oct 24, 2026, 5:39 AM EDT
Completed Not applicable Interventional

Transform Type 2: Examining Meal-Delivery and Education for Diabetes Self-Care

NCT04810026
View directory record Official record
Conditions
PreDiabetes, Diabetes Mellitus, Type 2
Interventions
Education, Meal delivery, Lifestyle coaching
Behavioral
Lead sponsor
UnitedHealth Group
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Minnetonka, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Oct 24, 2026, 5:39 AM EDT
Completed Phase 4 Interventional

CGM - Reimagine Primary Care

NCT04413578
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dexcom G6, Contour NextOne
Device
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years to 80 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Holladay, Utah • Murray, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 24, 2026, 5:39 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

iGlucose® Remote Patient Monitoring Device as an Adjunct to Routine Glucose Meter Devices for Glycemic Management and Control in Gestational Diabetes

NCT04206748
View directory record Official record
Conditions
Gestational Diabetes, Type2 Diabetes, Pregnancy in Diabetic
Interventions
iGlucose Smart Meter System, Routine Care-RX meter
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2021 · Synced Oct 24, 2026, 5:39 AM EDT
Withdrawn Not applicable Interventional

Continuous Glucose Monitoring Using a New Subcutaneous Insulin Protocol for Mild to Moderate Diabetic Ketoacidosis

NCT06693115
View directory record Official record
Conditions
Diabetic Ketoacidosis, Hyperglycemia
Interventions
CGM with alerts
Device
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 24, 2026, 5:39 AM EDT
Completed Not applicable Interventional Results available

ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study

NCT02613897
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Saxagliptin, Dapagliflozin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 24, 2026, 5:39 AM EDT
Completed Not applicable Interventional

Pet Ownership and Glucose Control in Type 1 Diabetes

NCT01733524
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Pet Fish, Picture of a fish
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
10 Years to 17 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Oct 24, 2026, 5:39 AM EDT
Completed Not applicable Interventional Results available

The Summer Camp Study 2: Blood Glucose Control With a Bi-Hormonal Endocrine Pancreas

NCT02105324
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Bionic Pancreas, Usual Care
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 11 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 24, 2026, 5:39 AM EDT
Terminated Phase 4 Interventional Results available

A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)

NCT02072096
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Glimepiride, Metformin, Pioglitazone, Acarbose, Linagliptin, Sitagliptin, Liraglutide, Insulin Glargine, Exenatide once weekly (QW), Exenatide twice daily (BID)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
65 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
16
States / cities
Miami, Florida • New Port Richey, Florida • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 24, 2026, 5:39 AM EDT
Recruiting Not applicable Interventional

NOURISH - A Healthcare-community Partnership to Improve Nutrition for Optimal Glycemic Control and Pregnancy Outcomes With Pregestational Diabetes

NCT07560813
View directory record Official record
Conditions
Type 2 Diabetes, Type 1 Diabetes, Pregnancy, High Risk
Interventions
Mid-Ohio Food Farmacy (MOF+) produce delivery, Nutrition education with Dining with Diabetes (DWD), Health Impact Ohio Central Ohio Pathways Hub to address unmet social needs
Dietary Supplement · Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 24, 2026, 5:39 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

NCT02058160
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Insulin glargine/lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Metformin (Background Drug)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
108
States / cities
Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 24, 2026, 5:39 AM EDT
Not yet recruiting Not applicable Interventional

OCM™ Treatment With Routine Care in Venous Leg Ulcers Compared to Routine Care Treatment Alone.

NCT07754526
View directory record Official record
Conditions
Venous Leg Ulcer (VLU)
Interventions
Omeza OCM™ Wound Matrix, Routine Care
Device · Procedure
Lead sponsor
Omeza, LLC
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 24, 2026, 5:39 AM EDT
Completed No phase listed Observational

Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control

NCT00806520
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Oct 24, 2026, 5:39 AM EDT
Completed Phase 2 Interventional Results available

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin

NCT01658579
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Temecula, California • Minneapolis, Minnesota • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Oct 24, 2026, 5:39 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide

NCT06657209
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes, Pre Diabetes
Interventions
Insulin resistance testing, OGTT, Fat biopsy, DXA scan, MRI, 1H-MRS, Tirzepatide, Pioglitazone
Procedure · Radiation · Drug
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 24, 2026, 5:39 AM EDT
Completed Not applicable Interventional

Electrophysiologic Changes in Blacks Treated With CBT for Insomnia

NCT02741336
View directory record Official record
Conditions
Insomnia
Interventions
Cognitive Behavioral Therapy for Insomnia (CBT-I), Self-Monitoring
Behavioral
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
30 Years to 50 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 24, 2026, 5:39 AM EDT
Completed Phase 2 Interventional Results available

A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator

NCT00631007
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
INT131 besylate, Pioglitazone HCl, Placebo
Drug
Lead sponsor
InteKrin Therapeutics, Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
59
States / cities
Carmichael, California • Los Angeles, California • San Diego, California + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Oct 24, 2026, 5:39 AM EDT